Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Improved Ocular Tissue Models and Eye-On-A-Chip Technologies Will Facilitate Ophthalmic Drug Development.

Wright CB, Becker SM, Low LA, Tagle DA, Sieving PA.

J Ocul Pharmacol Ther. 2019 Jun 5. doi: 10.1089/jop.2018.0139. [Epub ahead of print]

PMID:
31166829
2.

Mapping biologically active chemical space to accelerate drug discovery.

Sittampalam GS, Rudnicki DD, Tagle DA, Simeonov A, Austin CP.

Nat Rev Drug Discov. 2019 Feb;18(2):83-84. doi: 10.1038/d41573-018-00007-2. No abstract available.

PMID:
30710133
3.

Correction for Han et al., "Biochemical and Structural Properties of Mouse Kynurenine Aminotransferase III".

Han Q, Robinson H, Cai T, Tagle DA, Li J.

Mol Cell Biol. 2018 Apr 30;38(10). pii: e00099-18. doi: 10.1128/MCB.00099-18. Print 2018 May 15. No abstract available.

4.

Microphysiological Systems (Tissue Chips) and their Utility for Rare Disease Research.

Low LA, Tagle DA.

Adv Exp Med Biol. 2017;1031:405-415. doi: 10.1007/978-3-319-67144-4_23. Review.

PMID:
29214585
5.

Tissue chips - innovative tools for drug development and disease modeling.

Low LA, Tagle DA.

Lab Chip. 2017 Sep 12;17(18):3026-3036. doi: 10.1039/c7lc00462a. Review.

6.

Navigating tissue chips from development to dissemination: A pharmaceutical industry perspective.

Ewart L, Fabre K, Chakilam A, Dragan Y, Duignan DB, Eswaraka J, Gan J, Guzzie-Peck P, Otieno M, Jeong CG, Keller DA, de Morais SM, Phillips JA, Proctor W, Sura R, Van Vleet T, Watson D, Will Y, Tagle D, Berridge B.

Exp Biol Med (Maywood). 2017 Oct;242(16):1579-1585. doi: 10.1177/1535370217715441. Epub 2017 Jun 16.

7.

Organs-on-chips: Progress, challenges, and future directions.

Low LA, Tagle DA.

Exp Biol Med (Maywood). 2017 Oct;242(16):1573-1578. doi: 10.1177/1535370217700523. Epub 2017 Mar 26.

8.

Microphysiological Systems ("Organs-on-Chips") for Drug Efficacy and Toxicity Testing.

Low LA, Tagle DA.

Clin Transl Sci. 2017 Jul;10(4):237-239. doi: 10.1111/cts.12444. Epub 2017 Mar 7. No abstract available.

9.
10.

Diagnostic potential of extracellular RNA from biofluids.

Lombo TB, Ganguly A, Tagle DA.

Expert Rev Mol Diagn. 2016 Nov;16(11):1135-1138. Epub 2016 Oct 8. No abstract available.

PMID:
27682891
11.

Stem cell-derived models to improve mechanistic understanding and prediction of human drug-induced liver injury.

Goldring C, Antoine DJ, Bonner F, Crozier J, Denning C, Fontana RJ, Hanley NA, Hay DC, Ingelman-Sundberg M, Juhila S, Kitteringham N, Silva-Lima B, Norris A, Pridgeon C, Ross JA, Young RS, Tagle D, Tornesi B, van de Water B, Weaver RJ, Zhang F, Park BK.

Hepatology. 2017 Feb;65(2):710-721. doi: 10.1002/hep.28886. Epub 2016 Nov 30. Review.

12.

Good Cell Culture Practice for stem cells and stem-cell-derived models.

Pamies D, Bal-Price A, Simeonov A, Tagle D, Allen D, Gerhold D, Yin D, Pistollato F, Inutsuka T, Sullivan K, Stacey G, Salem H, Leist M, Daneshian M, Vemuri MC, McFarland R, Coecke S, Fitzpatrick SC, Lakshmipathy U, Mack A, Wang WB, Yamazaki D, Sekino Y, Kanda Y, Smirnova L, Hartung T.

ALTEX. 2017;34(1):95-132. doi: 10.14573/altex.1607121. Epub 2016 Aug 23.

13.

Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing.

Marx U, Andersson TB, Bahinski A, Beilmann M, Beken S, Cassee FR, Cirit M, Daneshian M, Fitzpatrick S, Frey O, Gaertner C, Giese C, Griffith L, Hartung T, Heringa MB, Hoeng J, de Jong WH, Kojima H, Kuehnl J, Leist M, Luch A, Maschmeyer I, Sakharov D, Sips AJ, Steger-Hartmann T, Tagle DA, Tonevitsky A, Tralau T, Tsyb S, van de Stolpe A, Vandebriel R, Vulto P, Wang J, Wiest J, Rodenburg M, Roth A.

ALTEX. 2016;33(3):272-321. doi: 10.14573/altex.1603161. Epub 2016 May 15. Review.

14.

Tissue Chips to aid drug development and modeling for rare diseases.

Low LA, Tagle DA.

Expert Opin Orphan Drugs. 2016;4(11):1113-1121. doi: 10.1080/21678707.2016.1244479. Epub 2016 Oct 19.

15.

The NIH Extracellular RNA Communication Consortium.

Ainsztein AM, Brooks PJ, Dugan VG, Ganguly A, Guo M, Howcroft TK, Kelley CA, Kuo LS, Labosky PA, Lenzi R, McKie GA, Mohla S, Procaccini D, Reilly M, Satterlee JS, Srinivas PR, Church ES, Sutherland M, Tagle DA, Tucker JM, Venkatachalam S.

J Extracell Vesicles. 2015 Aug 28;4:27493. doi: 10.3402/jev.v4.27493. eCollection 2015.

16.

Perspectives on best practices for gene therapy programs.

Cheever TR, Berkley D, Braun S, Brown RH, Byrne BJ, Chamberlain JS, Cwik V, Duan D, Federoff HJ, High KA, Kaspar BK, Klinger KW, Larkindale J, Lincecum J, Mavilio F, McDonald CL, McLaughlin J, Weiss McLeod B, Mendell JR, Nuckolls G, Stedman HH, Tagle DA, Vandenberghe LH, Wang H, Wernett PJ, Wilson JM, Porter JD, Gubitz AK.

Hum Gene Ther. 2015 Mar;26(3):127-33. doi: 10.1089/hum.2014.147. Epub 2015 Mar 3.

17.

Developing microphysiological systems for use as regulatory tools--challenges and opportunities.

Andersen ME, Betts K, Dragan Y, Fitzpatrick S, Goodman JL, Hartung T, Himmelfarb J, Ingber DE, Jacobs A, Kavlock R, Kolaja K, Stevens JL, Tagle D, Lansing Taylor D, Throckmorton D.

ALTEX. 2014;31(3):364-7. doi: 10.14573/altex.1405151. No abstract available.

18.

Organs-on-chips (microphysiological systems): tools to expedite efficacy and toxicity testing in human tissue.

Fabre KM, Livingston C, Tagle DA.

Exp Biol Med (Maywood). 2014 Sep;239(9):1073-7. doi: 10.1177/1535370214538916. Epub 2014 Jun 24. Review. No abstract available.

PMID:
24962171
19.

Expanding rare disease drug trials based on shared molecular etiology.

Brooks PJ, Tagle DA, Groft S.

Nat Biotechnol. 2014 Jun;32(6):515-8. doi: 10.1038/nbt.2924. No abstract available.

20.

Phenylketonuria Scientific Review Conference: state of the science and future research needs.

Camp KM, Parisi MA, Acosta PB, Berry GT, Bilder DA, Blau N, Bodamer OA, Brosco JP, Brown CS, Burlina AB, Burton BK, Chang CS, Coates PM, Cunningham AC, Dobrowolski SF, Ferguson JH, Franklin TD, Frazier DM, Grange DK, Greene CL, Groft SC, Harding CO, Howell RR, Huntington KL, Hyatt-Knorr HD, Jevaji IP, Levy HL, Lichter-Konecki U, Lindegren ML, Lloyd-Puryear MA, Matalon K, MacDonald A, McPheeters ML, Mitchell JJ, Mofidi S, Moseley KD, Mueller CM, Mulberg AE, Nerurkar LS, Ogata BN, Pariser AR, Prasad S, Pridjian G, Rasmussen SA, Reddy UM, Rohr FJ, Singh RH, Sirrs SM, Stremer SE, Tagle DA, Thompson SM, Urv TK, Utz JR, van Spronsen F, Vockley J, Waisbren SE, Weglicki LS, White DA, Whitley CB, Wilfond BS, Yannicelli S, Young JM.

Mol Genet Metab. 2014 Jun;112(2):87-122. doi: 10.1016/j.ymgme.2014.02.013. Epub 2014 Mar 6.

PMID:
24667081
21.

The National Institutes of Health Microphysiological Systems Program focuses on a critical challenge in the drug discovery pipeline.

Sutherland ML, Fabre KM, Tagle DA.

Stem Cell Res Ther. 2013;4 Suppl 1:I1. doi: 10.1186/scrt361. Epub 2013 Dec 20.

22.

Expression of E6, p53 and p21 proteins and physical state of HPV16 in cervical cytologies with and without low grade lesions.

Tagle DK, Sotelo DH, Illades-Aguiar B, Leyva-Vazquez MA, Alfaro EF, Coronel YC, Hernández Odel M, Romero Ldel C.

Int J Clin Exp Med. 2014 Jan 15;7(1):186-93. eCollection 2014.

23.

Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations.

Galpern WR, Corrigan-Curay J, Lang AE, Kahn J, Tagle D, Barker RA, Freeman TB, Goetz CG, Kieburtz K, Kim SY, Piantadosi S, Comstock Rick A, Federoff HJ.

Lancet Neurol. 2012 Jul;11(7):643-50. doi: 10.1016/S1474-4422(12)70064-9.

PMID:
22710757
24.

The human proteome - a scientific opportunity for transforming diagnostics, therapeutics, and healthcare.

Vidal M, Chan DW, Gerstein M, Mann M, Omenn GS, Tagle D, Sechi S; Workshop Participants.

Clin Proteomics. 2012 Jul 3;9(1):6. doi: 10.1186/1559-0275-9-6.

25.

An overview of the adaptive designs accelerating promising trials into treatments (ADAPT-IT) project.

Meurer WJ, Lewis RJ, Tagle D, Fetters MD, Legocki L, Berry S, Connor J, Durkalski V, Elm J, Zhao W, Frederiksen S, Silbergleit R, Palesch Y, Berry DA, Barsan WG.

Ann Emerg Med. 2012 Oct;60(4):451-7. doi: 10.1016/j.annemergmed.2012.01.020. Epub 2012 Mar 15.

26.

Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam principles).

Kinsinger CR, Apffel J, Baker M, Bian X, Borchers CH, Bradshaw R, Brusniak MY, Chan DW, Deutsch EW, Domon B, Gorman J, Grimm R, Hancock W, Hermjakob H, Horn D, Hunter C, Kolar P, Kraus HJ, Langen H, Linding R, Moritz RL, Omenn GS, Orlando R, Pandey A, Ping P, Rahbar A, Rivers R, Seymour SL, Simpson RJ, Slotta D, Smith RD, Stein SE, Tabb DL, Tagle D, Yates JR 3rd, Rodriguez H.

Proteomics Clin Appl. 2011 Dec;5(11-12):580-9. doi: 10.1002/prca.201100097.

PMID:
22213554
27.

Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam principles).

Kinsinger CR, Apffel J, Baker M, Bian X, Borchers CH, Bradshaw R, Brusniak MY, Chan DW, Deutsch EW, Domon B, Gorman J, Grimm R, Hancock W, Hermjakob H, Horn D, Hunter C, Kolar P, Kraus HJ, Langen H, Linding R, Moritz RL, Omenn GS, Orlando R, Pandey A, Ping P, Rahbar A, Rivers R, Seymour SL, Simpson RJ, Slotta D, Smith RD, Stein SE, Tabb DL, Tagle D, Yates JR, Rodriguez H.

Proteomics. 2012 Jan;12(1):11-20. doi: 10.1002/pmic.201100562. Epub 2011 Dec 14.

PMID:
22069307
28.

Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam Principles).

Kinsinger CR, Apffel J, Baker M, Bian X, Borchers CH, Bradshaw R, Brusniak MY, Chan DW, Deutsch EW, Domon B, Gorman J, Grimm R, Hancock W, Hermjakob H, Horn D, Hunter C, Kolar P, Kraus HJ, Langen H, Linding R, Moritz RL, Omenn GS, Orlando R, Pandey A, Ping P, Rahbar A, Rivers R, Seymour SL, Simpson RJ, Slotta D, Smith RD, Stein SE, Tabb DL, Tagle D, Yates JR, Rodriguez H.

J Proteome Res. 2012 Feb 3;11(2):1412-9. doi: 10.1021/pr201071t. Epub 2011 Dec 8.

29.

Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam Principles).

Kinsinger CR, Apffel J, Baker M, Bian X, Borchers CH, Bradshaw R, Brusniak MY, Chan DW, Deutsch EW, Domon B, Gorman J, Grimm R, Hancock W, Hermjakob H, Horn D, Hunter C, Kolar P, Kraus HJ, Langen H, Linding R, Moritz RL, Omenn GS, Orlando R, Pandey A, Ping P, Rahbar A, Rivers R, Seymour SL, Simpson RJ, Slotta D, Smith RD, Stein SE, Tabb DL, Tagle D, Yates JR 3rd, Rodriguez H.

Mol Cell Proteomics. 2011 Dec;10(12):O111.015446. doi: 10.1074/mcp.O111.015446. Epub 2011 Nov 3.

30.

Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage.

Shirendeb U, Reddy AP, Manczak M, Calkins MJ, Mao P, Tagle DA, Reddy PH.

Hum Mol Genet. 2011 Apr 1;20(7):1438-55. doi: 10.1093/hmg/ddr024. Epub 2011 Jan 21.

31.

Research challenges in central nervous system manifestations of inborn errors of metabolism.

Dickson PI, Pariser AR, Groft SC, Ishihara RW, McNeil DE, Tagle D, Griebel DJ, Kaler SG, Mink JW, Shapiro EG, Bjoraker KJ, Krivitzky L, Provenzale JM, Gropman A, Orchard P, Raymond G, Cohen BH, Steiner RD, Goldkind SF, Nelson RM, Kakkis E, Patterson MC.

Mol Genet Metab. 2011 Mar;102(3):326-38. doi: 10.1016/j.ymgme.2010.11.164. Epub 2010 Dec 2. Review.

32.
33.

Thermal stability, pH dependence and inhibition of four murine kynurenine aminotransferases.

Han Q, Cai T, Tagle DA, Li J.

BMC Biochem. 2010 May 19;11:19. doi: 10.1186/1471-2091-11-19.

34.

Structure, expression, and function of kynurenine aminotransferases in human and rodent brains.

Han Q, Cai T, Tagle DA, Li J.

Cell Mol Life Sci. 2010 Feb;67(3):353-68. doi: 10.1007/s00018-009-0166-4. Epub 2009 Oct 15. Review.

35.

Structural insight into the inhibition of human kynurenine aminotransferase I/glutamine transaminase K.

Han Q, Robinson H, Cai T, Tagle DA, Li J.

J Med Chem. 2009 May 14;52(9):2786-93. doi: 10.1021/jm9000874.

36.

Biochemical and structural properties of mouse kynurenine aminotransferase III.

Han Q, Robinson H, Cai T, Tagle DA, Li J.

Mol Cell Biol. 2009 Feb;29(3):784-93. doi: 10.1128/MCB.01272-08. Epub 2008 Nov 24. Erratum in: Mol Cell Biol. 2018 Apr 30;38(10 ):.

37.

Substrate specificity and structure of human aminoadipate aminotransferase/kynurenine aminotransferase II.

Han Q, Cai T, Tagle DA, Robinson H, Li J.

Biosci Rep. 2008 Aug;28(4):205-15. doi: 10.1042/BSR20080085.

38.

HUPO Brain Proteome Project: summary of the pilot phase and introduction of a comprehensive data reprocessing strategy.

Hamacher M, Apweiler R, Arnold G, Becker A, Blüggel M, Carrette O, Colvis C, Dunn MJ, Fröhlich T, Fountoulakis M, van Hall A, Herberg F, Ji J, Kretzschmar H, Lewczuk P, Lubec G, Marcus K, Martens L, Palacios Bustamante N, Park YM, Pennington SR, Robben J, Stühler K, Reidegeld KA, Riederer P, Rossier J, Sanchez JC, Schrader M, Stephan C, Tagle D, Thiele H, Wang J, Wiltfang J, Yoo JS, Zhang C, Klose J, Meyer HE.

Proteomics. 2006 Sep;6(18):4890-8. Erratum in: Proteomics. 2006 Oct;6(20):5674. Ji, Juango [corrected to Ji, Jianguo].

PMID:
16927433
39.

Characterization of kynurenine aminotransferase III, a novel member of a phylogenetically conserved KAT family.

Yu P, Li Z, Zhang L, Tagle DA, Cai T.

Gene. 2006 Jan 3;365:111-8. Epub 2006 Jan 10.

PMID:
16376499
40.

Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease.

Sapko MT, Guidetti P, Yu P, Tagle DA, Pellicciari R, Schwarcz R.

Exp Neurol. 2006 Jan;197(1):31-40. Epub 2005 Aug 15.

PMID:
16099455
41.

Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements.

DiProspero NA, Chen EY, Charles V, Plomann M, Kordower JH, Tagle DA.

J Neurocytol. 2004 Sep;33(5):517-33.

PMID:
15906159
42.

Glutamic acid decarboxylase autoimmunity in Batten disease and other disorders.

Pearce DA, Atkinson M, Tagle DA.

Neurology. 2004 Dec 14;63(11):2001-5. Review.

PMID:
15596740
43.

Biochemical and phenotypic abnormalities in kynurenine aminotransferase II-deficient mice.

Yu P, Di Prospero NA, Sapko MT, Cai T, Chen A, Melendez-Ferro M, Du F, Whetsell WO Jr, Guidetti P, Schwarcz R, Tagle DA.

Mol Cell Biol. 2004 Aug;24(16):6919-30.

44.

Targeted deletion of the kynurenine aminotransferase ii gene reveals a critical role of endogenous kynurenic acid in the regulation of synaptic transmission via alpha7 nicotinic receptors in the hippocampus.

Alkondon M, Pereira EF, Yu P, Arruda EZ, Almeida LE, Guidetti P, Fawcett WP, Sapko MT, Randall WR, Schwarcz R, Tagle DA, Albuquerque EX.

J Neurosci. 2004 May 12;24(19):4635-48.

45.

Overexpression and nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase in a transgenic mouse model of Huntington's disease.

Senatorov VV, Charles V, Reddy PH, Tagle DA, Chuang DM.

Mol Cell Neurosci. 2003 Mar;22(3):285-97.

PMID:
12691731
46.

PACSIN 1 interacts with huntingtin and is absent from synaptic varicosities in presymptomatic Huntington's disease brains.

Modregger J, DiProspero NA, Charles V, Tagle DA, Plomann M.

Hum Mol Genet. 2002 Oct 1;11(21):2547-58.

PMID:
12354780
47.

Striatal neurochemical changes in transgenic models of Huntington's disease.

Ariano MA, Aronin N, Difiglia M, Tagle DA, Sibley DR, Leavitt BR, Hayden MR, Levine MS.

J Neurosci Res. 2002 Jun 15;68(6):716-29.

PMID:
12111832
48.
49.

Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease.

Laforet GA, Sapp E, Chase K, McIntyre C, Boyce FM, Campbell M, Cadigan BA, Warzecki L, Tagle DA, Reddy PH, Cepeda C, Calvert CR, Jokel ES, Klapstein GJ, Ariano MA, Levine MS, DiFiglia M, Aronin N.

J Neurosci. 2001 Dec 1;21(23):9112-23.

50.

Supplemental Content

Support Center